Vectibix (panitumumab)

PROGRAM RATIONALE

Client Requested: The intent of the criteria is to ensure that patients follow selection elements established by Clover Health for Vectibix.

CRITERIA FOR APPROVAL

- 1. What is the patient's diagnosis?
 - a. Colorectal cancer (including appendiceal adenocarcinoma and anal adenocarcinoma
 - b. Other
- 2. Is the patient currently receiving therapy with the requested medication?

Yes

No

Continuation criteria

3. Is the patient receiving benefit from therapy with the requested medication as defined as no evidence of unacceptable toxicity and no evidence of disease progression while on the current regimen?

Yes

No

Initiation criteria

- 20. What is the clinical setting in which the requested medication will be used?
 - a. Unresectable/inoperable disease
 - b. Advanced disease
 - c. Metastatic disease
 - d. None of the above
- 21. Did the patient previously experience clinical failure on cetuximab (Erbitux)?

Yes

No

- 22. What is the patient's RAS (KRAS and NRAS) mutation status? If 'Negative,' attach supporting chart note(s) confirming negative (wild-type) RAS (KRAS and NRAS) mutation status.
 - a. Negative (wild-type) for KRAS and NRAS mutations
 - b. Positive for KRAS and/or NRAS mutation(s)
 - c. Unknown
- 23. Will the requested medication be used in combination with encorafenib (Braftovi)?

Yes

No

24. Is the tumor positive for BRAF V600E mutation? If yes, attach supporting chart note(s) confirming positive BRAF V600E mutation status.

Yes

No

Vectibix C22984-A Clover MedB 12-2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s) C22984-A

SUMMARY OF EVIDENCE

1. Vectibix [package insert]. Thousand Oaks, CA: Amgen Inc.; August 2021.

EXPLANATION OF RATIONALE

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

Vectibix C22984-A Clover MedB 12-2023.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

 $\hfill \odot$ 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of